SNRPD2 Antibody

What is SNRPD2 and what is its biological function?

SNRPD2 (small nuclear ribonucleoprotein D2 polypeptide 16.5kDa) plays a crucial role in pre-mRNA splicing as a core component of the spliceosomal U1, U2, U4, and U5 small nuclear ribonucleoproteins (snRNPs). These structures serve as the building blocks of the spliceosome . SNRPD2 is a component of both pre-catalytic spliceosome B complex and activated spliceosome C complexes, and is also involved in the splicing of U12-type introns in pre-mRNAs as part of the minor spliceosome . The protein has a calculated molecular weight of approximately 14 kDa but is typically observed at 14-16 kDa in experimental conditions . Its function is essential for proper gene expression through its participation in intron removal during RNA processing.

Several types of SNRPD2 antibodies are available, each with specific characteristics:

Polyclonal antibodies often provide broader epitope recognition, while monoclonal antibodies offer higher specificity for a single epitope. Recombinant monoclonal antibodies provide consistent lot-to-lot reproducibility compared to hybridoma-derived monoclonals .

How do I optimize SNRPD2 antibody dilutions for different experimental techniques?

Optimizing antibody dilutions is critical for achieving specific signal while minimizing background:

For Western Blot optimization:

• Start with the manufacturer's recommended range (e.g., 1:500-1:2400 for Proteintech 14789-1-AP)

• Perform a dilution series (e.g., 1:500, 1:1000, 1:2000)

• Include positive controls such as A2780, A549, or HL-60 cell lysates, which have been validated to express SNRPD2

• For Abcam's EPR16762 antibody, a higher dilution (1:20000) has been validated with HepG2 cell lysate

• Use blocking with 5% non-fat dry milk in TBST to reduce background

For IHC optimization:

• Begin with recommended range (e.g., 1:20-1:200)

• Test antigen retrieval methods: Both TE buffer (pH 9.0) and citrate buffer (pH 6.0) have been validated

• Validated positive controls include human skin tissue, human lung tissue, and human lung cancer tissue

Optimization should include negative controls (isotype control or secondary antibody only) to assess background staining levels.

How can I validate the specificity of an SNRPD2 antibody?

Validating antibody specificity is essential to ensure experimental reliability:

• Multiple application validation: Test the antibody in different applications (WB, IHC, IP) to confirm consistent target recognition

• Molecular weight verification: Confirm detection at the expected molecular weight of 14-16 kDa

• Knockdown/knockout validation:

  • Perform siRNA knockdown of SNRPD2

  • Compare antibody signal between control and knockdown samples

  • Expected result: Significant reduction in signal intensity in knockdown samples

• Positive control samples: Use cell lines with confirmed SNRPD2 expression, such as:

  • A2780 cells

  • A549 cells

  • HL-60 cells

  • HepG2 cells

• Cross-reactivity testing: If studying non-human samples, verify species cross-reactivity. Some SNRPD2 antibodies have validated reactivity with mouse and rat samples in addition to human samples .

What are the optimal sample preparation methods for detecting SNRPD2?

Proper sample preparation significantly impacts SNRPD2 detection quality:

For Western Blot:

• Complete cell lysis is crucial using buffers containing appropriate detergents (RIPA or NP-40)

• Include protease inhibitors to prevent degradation

• Heat samples at 95°C for 5 minutes in reducing sample buffer

• Load 20-30 μg of total protein per lane (based on HepG2 lysate loading of 20 μg)

• Use fresh samples when possible; if stored, maintain at -80°C with aliquoting to avoid freeze-thaw cycles

For IHC:

• Fixation with 10% neutral buffered formalin is recommended

• Antigen retrieval is essential - use either:

  • TE buffer pH 9.0 (preferred method)

  • Citrate buffer pH 6.0 (alternative method)

• Paraffin embedding and sectioning at 4-5 μm thickness typically yields optimal results

For Flow Cytometry:

• Fixation with 4% paraformaldehyde

• Complete permeabilization is essential for nuclear protein detection

• Blocking with appropriate serum (5-10%) to reduce non-specific binding

How is SNRPD2 expression associated with disease states?

SNRPD2 has been implicated in several pathological conditions:

COVID-19 Reinfection:

• SNRPD2 was identified as a hub gene in COVID-19 patients who retest positive (RTP) after initial recovery

• SNRPD2 is upregulated in RTP patients compared to convalescent COVID-19 patients

• May be involved in regulating mRNA splicing machinery that SARS-CoV-2 uses to evade host challenges

• Potential biomarker for predicting RTP status in COVID-19 patients

Neurodegenerative Conditions:

• SNRPD2 expression is highly associated with Alzheimer's disease based on KEGG pathway analysis

• May represent a link between RNA processing defects and neurodegenerative pathology

Hepatocellular Carcinoma (HCC):

Autoimmune Disorders:

• SNRPD2 is one of the Sm proteins that can be targets of autoantibodies in systemic lupus erythematosus (SLE)

• These autoantibodies serve as diagnostic hallmarks in systemic autoimmune diseases

What experimental approaches can be used to study SNRPD2's role in alternative splicing?

Investigating SNRPD2's function in splicing requires sophisticated methodologies:

• Minigene Reporter Assays:

  • Design a splicing reporter construct containing introns and exons of interest

  • Example: A minigene reporter containing intron 5, exon 5, intron 6, exon 6, and intron 7 of DDX39A in pCDNA5 plasmid was used to study SNRPD2's role in DDX39A splicing

  • Manipulate SNRPD2 expression levels (overexpression or knockdown)

  • Analyze splicing patterns via RT-PCR and calculate percent spliced-in (PSI) values

• RNA-Seq with Differential Splicing Analysis:

  • Perform SNRPD2 knockdown or overexpression

  • Conduct RNA-sequencing

  • Analyze alternative splicing events using tools like rMATS (replicate multivariate analysis of transcript splicing)

  • Categorize affected events (e.g., intron retention, exon skipping)

  • Validate findings with RT-PCR

• Co-immunoprecipitation (Co-IP) Studies:

  • Use anti-SNRPD2 antibodies to pull down protein complexes

  • Perform mass spectrometry to identify interacting partners

  • Validate interactions with reciprocal Co-IP and western blotting

• In Vivo Crosslinking and Immunoprecipitation (CLIP):

  • UV crosslink RNA-protein complexes

  • Immunoprecipitate SNRPD2

  • Sequence bound RNAs to identify direct RNA targets and binding sites

How can I study SNRPD2's involvement in post-translational modifications and protein interactions?

SNRPD2 undergoes regulatory post-translational modifications that affect its function:

Ubiquitination Studies:

• SNRPD2 is a substrate for the E3 ubiquitin ligase activity of Salmonella SlrP

• Experimental approach:

  • In vitro ubiquitination assays with purified components

  • Mass spectrometry to identify modified lysine residues (K85 and K92 are among the SlrP-targeted sites)

  • Mutation of specific lysine residues to validate ubiquitination sites

Protein-Protein Interaction Analysis:

• Yeast two-hybrid screening has successfully identified SNRPD2 interactions

• Proximity-based labeling approaches (BioID or APEX)

• Crosslinking mass spectrometry to identify interactions within spliceosomal complexes

Subcellular Localization:

• Immunofluorescence with anti-SNRPD2 antibodies showing primarily nuclear localization

• Live-cell imaging with fluorescently tagged SNRPD2

• Subcellular fractionation followed by western blotting

What controls and considerations are critical when studying SNRPD2 in different disease models?

When investigating SNRPD2 in disease contexts, several experimental considerations are vital:

For Cancer Research:

For Neurodegenerative Disease Research:

• Consider age-matched controls due to potential age-related changes in splicing machinery

• Use both in vitro neuronal models and patient-derived samples when possible

• Correlate findings with clinical parameters and cognitive scores

For Infectious Disease Studies:

• Use appropriate biosafety levels when studying SNRPD2 in the context of pathogens like SARS-CoV-2

• Include time-course experiments to capture dynamic changes in SNRPD2 expression

• Consider paired samples from the same patients at different disease stages

Universal Considerations:

• Validate antibody specificity in the specific disease model

• Include appropriate statistical analyses based on sample sizes

• Consider sex as a biological variable when analyzing SNRPD2 expression and function

How can I troubleshoot weak or absent SNRPD2 signal in Western blot?

When encountering detection issues in Western blot experiments:

• Sample preparation issues:

  • Ensure complete lysis (sonication may help with nuclear proteins)

  • Verify protein concentration with accurate quantification

  • Check sample degradation with a well-established housekeeping protein

• Antibody-related considerations:

  • Try reducing antibody dilution (e.g., from 1:2000 to 1:500)

  • Extend primary antibody incubation (overnight at 4°C)

  • Consider a different SNRPD2 antibody that targets a different epitope

  • Use fresh antibody aliquots to avoid freeze-thaw degradation

• Protocol optimizations:

  • Increase protein loading (30-50 μg)

  • Optimize transfer conditions for small proteins (~14-16 kDa)

  • Use PVDF membrane instead of nitrocellulose for better protein retention

  • Extend exposure time for detection

• Other factors:

  • Verify if your cell type/tissue expresses detectable levels of SNRPD2

  • Consider that SNRPD2 expression may be altered in your experimental conditions

How can I minimize background in immunohistochemistry with SNRPD2 antibodies?

High background in IHC can obscure specific SNRPD2 staining:

• Optimize blocking:

  • Extend blocking time (1-2 hours)

  • Try different blocking agents (BSA, normal serum, commercial blockers)

  • Include 0.1-0.3% Triton X-100 to reduce non-specific binding

• Antibody optimization:

  • Titrate antibody concentration (start with higher dilutions like 1:200)

  • Reduce primary antibody incubation time or temperature

  • Use antibody diluent with background-reducing components

• Tissue preparation:

  • Ensure complete deparaffinization

  • Try different antigen retrieval methods (compare TE buffer pH 9.0 vs. citrate buffer pH 6.0)

  • Quench endogenous peroxidases thoroughly (3% H₂O₂, 10-15 minutes)

• Controls to include:

  • Secondary antibody-only control to check for non-specific binding

  • Isotype control to rule out Fc receptor binding

  • Positive control tissues with known SNRPD2 expression (human skin, lung)

What are emerging techniques for studying SNRPD2 function beyond traditional antibody applications?

As research on splicing factors advances, several cutting-edge approaches offer new insights:

• CRISPR-based technologies:

  • CRISPR knockout/knockin for precise genetic manipulation of SNRPD2

  • CRISPRi for tunable repression of SNRPD2 expression

  • CRISPR activation systems to upregulate endogenous SNRPD2

• Single-cell approaches:

  • Single-cell RNA-seq to examine cell-type-specific SNRPD2 splicing functions

  • Single-cell proteomics to assess SNRPD2 protein levels in heterogeneous samples

• Live-cell imaging:

  • SNAP/CLIP-tag fusions for real-time SNRPD2 visualization

  • FRET-based reporters to monitor SNRPD2 interactions

• Therapeutic targeting:

  • Small molecule screening for SNRPD2 modulators (e.g., digitoxin has been found to interact directly with SNRPD2 in HCC)

  • Antisense oligonucleotides to modulate SNRPD2-dependent splicing events

These emerging technologies complement traditional antibody-based approaches and can provide new insights into SNRPD2 biology and potential therapeutic applications.

How might SNRPD2 serve as a biomarker or therapeutic target in disease?

Based on current research, SNRPD2 shows promise in multiple clinical applications:

As a Biomarker:

• In hepatocellular carcinoma:

  • SNRPD2 protein expression correlates with poor prognosis

  • Could potentially serve as a prognostic marker for patient stratification

  • Expression levels correlate with 39A_S expression, offering a potential combination biomarker

• In COVID-19:

  • SNRPD2 upregulation is associated with retesting positive status

  • Could help identify patients at risk for viral reactivation

As a Therapeutic Target:

• In cancer:

  • The SNRPD2-DDX39A-MYC axis represents a potential intervention point

  • Digitoxin directly interacts with SNRPD2 and shows cancer-suppressive effects in HCC models

• In infectious disease:

  • The interaction between bacterial effectors (like SlrP) and SNRPD2 could be targeted to prevent pathogen-mediated manipulation of host splicing

• In neurodegenerative conditions:

  • Modulating SNRPD2 activity could potentially affect splicing patterns relevant to disease progression